Veritas Genetics, which offered to sequence people’s genomes for rock-bottom prices, will cease US operations after it failed to raise a new round of financing.
Low price: The company, based in Boston, had tried to entice consumers to get their genome sequenced by lowering the price to $599 last July.
At that cost, Veritas was losing money on every genome. But it hoped to introduce a Netflix-like subscription model; customers would pay ongoing fees to learn new things from their DNA, such as disease risk predictions.
The company had sequenced between 5,000 and 10,000 genomes so far but there were signs that demand for the service was weak.
China worry: A person familiar with the company said it was going out of business in the US because it could not find new investors given concerns it had previously taken money from China.
Real Life. Real News. Real Voices
Help us tell more of the stories that matterBecome a founding member
Veritas’ main investors are all Chinese. They are Lilly Asia Venture, Simcere Pharmaceutical, and TrustBridge Partners.
The US has warned companies working in sensitive areas, including DNA data, over taking Chinese funds. In June, US regulators forced the sale of another American health company, PatientsLikeMe, because its primary investor was in China.
Veritas had been trying to raise between $50 to $75 million since earlier this year, this person said, but new investors balked at the Chinese ownership.
The company says it is going to try to make a comeback and continues operations overseas. “I can clarify this temporarily affects US operations only,” Mirza Cifric, the CEO of Veritas, said in an email. He said customers outside the US would continue to be served.
Subscribe to the newsletter news
We hate SPAM and promise to keep your email address safe